Understanding the oestrogen action in experimental and clinical atherosclerosis

Fundamental and Clinical Pharmacology

Volumn 20, Issue 6, 2006, Pages 539-548

  Arnal, J F ^a   Douin Echinard, V ^a   Brouchet, L ^a   Tremollieres F ^a   Laurell, H ^a   Lenfant, F ^a   Gadeau, A P ^b   Guery, J C ^c   Gourdy, P ^a  

^a CHU RANGUEIL   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

Author keywords

Atherosclerosis; Endothelium; Immuno inflammatory system; Mouse; Oestrogen; Oestrogen receptor

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GESTAGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; PROSTACYCLIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; CORONARY RISK; CYTOKINE PRODUCTION; ENDOTHELIUM LESION; EPITHELIZATION; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HEART PROTECTION; HORMONAL REGULATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; INFLAMMATION; LIPID OXIDATION; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MODELS, ANIMAL;

EID: 33751056346     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00445.x     Document Type: Review

References (82)

1. Hulley S., Grady D., Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280 605-613.
2. Rossouw J.E., Anderson G.L., Prentice R.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288 321-333.
3. Hodgin J., Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology (2002) 143 4495-4501.
4. Waters D.D., Gordon D., Rossouw J.E. et al. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials.. Circulation (2004) 109 e53-e55.
5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8 1211-1217.
6. Gimbrone M.A., Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am. J. Pathol. (1999) 155 1-5.
7. Shyy J.Y., Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ. Res. (2002) 91 769-775.
8. Tricot O., Mallat Z., Heymes C., Belmin J., Leseche G., Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation (2000) 101 2450-2453.
9. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. (1999) 340 115-125.
10. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. (2006) 86 515-581.
11. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. (2002) 91 281-291.
12. Libby P. Inflammation in atherosclerosis. Nature (2002) 420 868-874.
13. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (1992) 258 468-471.
14. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. (1995) 92 8264-8268.
15. Dansky H., Charlton S., McGee Harper M., Smith J. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. (1997) 94 4642-4646.
16. Binder C.J., Chang M.K., Shaw P.X. et al. Innate and acquired immunity in atherogenesis. Nat. Med. (2002) 8 1218-1226.
17. Massberg S., Brand K., Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. (2002) 196 887-896.
18. Clarkson T.B., Appt S.E. Controversies about HRT - lessons from monkey models. Maturitas (2005) 51 64-74.
19. Arnal J.F., Gourdy P., Elhage R. et al. Estrogens and atherosclerosis. Eur. J. Endocrinol. (2004) 150 113-117.
20. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science (2005) 308 1583-1587.
21. Bourassa P.A., Milos P.M., Gaynor B.J., Breslow J.L., Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. (1996) 93 10022-10027.
22. Elhage R., Arnal J.F., Pierragi M.-T. et al. Estradiol-17b prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscl. Thromb. Vasc. Biol. (1997) 17 2679-2684.
23. Haarbo J., Leth-Espensen P., Stender S., Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J. Clin. Invest. (1991) 87 1274-1279.
24. Holm P., Andersen H.L., Andersen M.R., Erhardtsen E., Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation (1999) 100 1727-1733.
25. Elhage R., Clamens S., Reardon-Alulis C. et al. Loss of atheroprotective effect of estradiol in immunodeficient mice. Endocrinology (2000) 141 462-465.
26. Elhage R., Gourdy P., Brouchet L. et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am. J. Pathol. (2004) 165 2013-2018.
27. Elhage R., Gourdy P., Huc X. et al. The atheroprotective effect of 17-estradiol depends on complex interactions in adaptive immunity. Am. J. Pathol. (2005) 167 267-274.
28. Ghisletti S., Meda C., Maggi A., Vegeto E. 17{beta}-Estradiol inhibits inflammatory gene expression by controlling NF-{kappa}B intracellular localization. Mol. Cell. Biol. (2005) 25 2957-2968.
29. Deshpande R., Khalili H., Pergolizzi R.G., Michael S.D., Chang M.D. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am. J. Reprod. Immunol. (1997) 38 46-54.
30. Vegeto E., Belcredito S., Etteri S. et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. U.S.A. (2003) 100 9614-9619.
31. Vegeto E., Bonincontro C., Pollio G. et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci. (2001) 21 1809-1818.
32. Soucy G., Boivin G., Labrie F., Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J. Immunol. (2005) 174 6391-6398.
33. Maret A., Coudert J.D., Garidou L. et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur. J. Immunol. (2003) 33 512-521.
34. Gourdy P., Araujo L.M., Zhu R. et al. Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN-{gamma} production by invariant natural killer T cells. Blood (2005) 105 2415-2420.
35. Delpy L., Douin-Echinard V., Garidou L., Bruand C., Saoudi A., Guery J.C. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J. Immunol. (2005) 175 5050-5057.
36. Paharkova-Vatchkova V., Maldonado R., Kovats S. Estrogen preferentially promotes the differentiation of CD11c+ CD11b (intermediate) dendritic cells from bone marrow precursors. J. Immunol. (2004) 172 1426-1436.
37. Mendelsohn M.E. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ. Res. (2000) 87 956-960.
38. Arnal J.F., Clamens S., Pechet C. et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc. Natl. Acad. Sci. U.S.A. (1996) 93 4108-4113.
39. Wagner A.H., Schroeter M.R., Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J. (2001) 15 2121-2130.
40. Elhage R., Bayard F., Richard V. et al. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation (1997) 96 3048-3052.
41. Egan K.M., Lawson J.A., Fries S. et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 306 1954-1957.
42. Manson J.E., Hsia J., Johnson K.C. et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. (2003) 349 523-534.
43. Anderson G.L., Limacher M., Assaf A.R. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291 1701-1712.
44. Koh K.K., Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler. Thromb. Vasc. Biol. (2004) 24 1171-1179.
45. Miyagawa K., Rosch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. (1997) 3 324-327.
46. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. (1999) 20 358-417.
47. Tora L., White J., Brou C. et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell (1989) 59 477-487.
48. Reid G., Denger S., Kos M., Gannon F. Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell. Mol. Life Sci. (2002) 59 821-831.
49. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. U.S.A. (1993) 90 11162-11166.
50. Couse J.F., Curtis S.W., Washburn T.F. et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol. Endocrinol. (1995) 9 1441-1454.
51. Pendaries C., Darblade B., Rochaix P. et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc. Natl. Acad. Sci. U.S.A. (2002) 99 2205-2210.
52. Kos M., Denger S., Reid G., Korach K.S., Gannon F. Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. J. Mol. Endocrinol. (2002) 29 281-286.
53. Flouriot G., Brand H., Denger S. et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. (2000) 19 4688-4700.
54. Metivier R., Penot G., Carmouche R.P. et al. Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J. (2004) 23 3653-3666.
55. Faye J.C., Fargin A., Bayard F. Dissimilarities between the uterine estrogen receptor in cytosol of castrated and estradiol-treated rats. Endocrinology (1986) 118 2276-2283.
56. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. (2003) 100 4807-4812.
57. Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development (2000) 127 4277-4291.
58. Darblade B., Pendaries C., Krust A. et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ. Res. (2002) 90 413-419.
59. Hodgin J.B., Krege J.H., Reddick R.L., Korach K.S., Smithies O., Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in ApoE-/- mice. J. Clin. Invest. (2001) 107 333-340.
60. Bennett M.R., O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol. Ther. (2001) 91 149-166.
61. Carmeliet P., Moos L., Stassen J. et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am. J. Pathol. (1997) 150 761-776.
62. Brouchet L., Krust A., Dupont S., Chambon P., Bayard F., Arnal J.F. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation (2001) 103 423-428.
63. Lindner V., Fingerle J., Reidy M.A. Mouse model of arterial injury. Circ. Res. (1993) 73 792-796.
64. Iwakura A., Luedemann C., Shastry S. et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation (2003) 108 3115-3121.
65. Iafrati M.D., Karas R.H., Aronovitz M. et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat. Med. (1997) 3 545-548.
66. Pare G., Krust A., Karas R.H. et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. (2002) 90 1087-1092.
67. Strehlow K., Werner N., Berweiler J. et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation (2003) 107 3059-3065.
68. Turgeon J.L., McDonnell D.P., Martin K.A., Wise P.M. Hormone therapy: physiological complexity belies therapeutic simplicity. Science (2004) 304 1269-1273.
69. Scarabin P.Y., Oger E., Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 362 428-432.
70. Yilmazer M., Fenkci V., Fenkci S. et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy post-menopausal women. Maturitas (2003) 46 245-253.
71. Hays J., Ockene J.K., Brunner R.L. et al. Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med. (2003) 348 1839-1854.
72. Grady D. Postmenopausal hormones - therapy for symptoms only. N. Engl. J. Med. (2003) 348 1835-1837.
73. Manson J.E., Bassuk S.S., Harman S.M. et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause (2006) 13 139-147.
74. de Lignieres B, de Vathaire F., Fournier S. et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric (2002) 5 332-340.
75. Fournier A., Berrino F., Riboli E., Avenel V., Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer. (2005) 114 448-454.
76. Kousteni S., Bellido T., Plotkin L.I. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 104 719-730.
77. Haynes M.P., Li L., Russell K.S., Bender J.R. Rapid vascular cell responses to estrogen and membrane receptors. Vascul. Pharmacol. (2002) 38 99-108.
78. Warner M., Gustafsson J.A. Nongenomic effects of estrogen: why all the uncertainty? Steroids (2006) 71 91-95.
79. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr. Rev. (1999) 20 418-434.
80. Jordan V.C. The past, present, and future of selective estrogen receptor modulation. Ann. N. Y. Acad. Sci. (2001) 949 72-79.
81. Jordan V.C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. (2001) 61 5683-5687.
82. Katzenellenbogen B.S., Katzenellenbogen J.A. Biomedicine. Defining the 'S' in SERMs. Science (2002) 295 2380-2381.